

A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease

NCT07319598

Status	RECRUITING
Phase	Phase 4
Sponsor	Peking University Third Hospital
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (6)

- Patients who voluntarily participate and sign the informed consent form
 - Male or female patients aged 18-80 years (inclusive)
 - Patients meeting the diagnostic criteria for connective tissue disease-related interstitial lung disease per the 2018 Chinese Expert Consensus at screening
 - FVC \geq 40% of predicted value at screening
 - Fertile male or female patients must agree to use effective contraception from signing informed consent until 3 months after the last study drug dose (Exemptions: postmenopausal women \geq 50 years with amenorrhea for \geq 1 year, or surgically sterilized women)
- ... and 1 more (see full listing online)

Exclusion (14)

- Treatment with tetrandrine or other antifibrotic drugs within 1 month before screening
 - Diabetes with fasting blood glucose greater than 11.1 mmol per L
 - Resting arterial oxygen partial pressure less than 50 mmHg
 - Active peptic ulcers or bleeding disorders
 - Tumors with expected survival less than 1 year
- ... and 9 more (see full listing online)

Locations (1 total)

Peking University Third Hospital, Beijing, China